Lexeo Therapeutics' CEO on using gene therapy for cardiovascular and Alzheimer's disease
- blonca9
- Feb 2, 2024
- 1 min read
Noland Townsend describes the science behind Lexeo's lead programs, including ones in the clinic for APOE4 homozygous patients and Friedreich’s Ataxia cardiomyopathy.
